ARCHIVE 2007

Invision completes the second closing of its Invision IV fund with CHF 168 million (EUR 101 million)

Zug, Switzerland, 12th July 2007

The private equity group Invision based in Zug, Switzerland, announces the second closing of its new private equity fund “Invision IV” with CHF 168 million (EUR 101 million) on 29th June 2007. Invision invests in European growth companies.

Invision invests between EUR 5 and 15 million in high growth companies with established business models and revenues from EUR 5 to 80 million. The focus is on European companies with well-positioned products in the IT, telecommunications, medical technology and innovative service products sectors.

Pension funds, family offices, fund of funds as well as private individuals are among Invision IV’s investors; many who have already participated in Invision’s earlier funds. Invision IV is managed as a limited partnership. Invision IV is expecting further commitments of capital from institutional and private investors.

About Invision:

Invision is celebrating its tenth anniversary this year and looks back on a successful decade. The Group has supported 62 companies during the past ten years and invested more than CHF 300 million (EUR 200 million). Over 40 of these holdings have been successfully sold to date. A total return of 2.8 times the invested capital was generated. The core team including Prof. Dr. Cuno Pümpin (Chairman of the Board), Dr. Bernd Pfister (Board Delegate and CEO), Gerhard Weisschädel (Board Member), Frank Becker (CFO), Martin Staub, Christian Stoller, Marco Martelli and Catherine Pümpin has substantial management and business experience which further is complemented by a broad, international network of industry experts.

The existing Invision III partnership has successfully completed the first half-year of 2007. Cosmo Pharmaceuticals had its successful IPO at SWX Swiss Exchange and Active Investor sold together with the other shareholders Plus Orthopedics for a total of CHF 1086 million in cash, including assumed debt, to Smith & Nephew. With these transactions Invision III has realized eight of its portfolio companies via Trade Sales or IPOs.

Dr. Bernd Pfister, Invision’s CEO, views the present investment environment positively: “As one of the few, well-experienced investors in this market segment, we are well positioned to offer capital, management expertise and a broad industrial network to support growth companies.”

For further information:

Invision Private Equity AG
Dr. Bernd Pfister, CEO
Grafenaustrasse 7
CH - 6304 Zug, Switzerland
Phone: +41 41 729 01 01
Email: pfister@invision.ch